Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent
Executive Summary
Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.